Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Long-Term Investments (2017 - 2026)

Corcept Therapeutics (CORT) has disclosed Long-Term Investments for 10 consecutive years, with $177.3 million as the latest value for Q1 2026.

  • For Q1 2026, Long-Term Investments fell 28.54% year-over-year to $177.3 million; the TTM value through Mar 2026 reached $177.3 million, down 28.54%, while the annual FY2025 figure was $160.3 million, 27.09% down from the prior year.
  • Long-Term Investments hit $177.3 million in Q1 2026 for Corcept Therapeutics, up from $160.3 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $248.0 million in Q1 2025 and bottomed at $4.9 million in Q3 2022.
  • Average Long-Term Investments over 5 years is $97.9 million, with a median of $59.6 million recorded in 2023.
  • Year-over-year, Long-Term Investments plummeted 96.34% in 2022 and then soared 1118.0% in 2023.
  • Corcept Therapeutics' Long-Term Investments stood at $4.9 million in 2022, then skyrocketed by 1055.77% to $57.2 million in 2023, then soared by 284.48% to $219.8 million in 2024, then dropped by 27.09% to $160.3 million in 2025, then grew by 10.6% to $177.3 million in 2026.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $177.3 million, $160.3 million, and $102.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.